[go: up one dir, main page]

TN2010000062A1 - Pyrrolidin -2-one derivatives as androgen receptor modulator - Google Patents

Pyrrolidin -2-one derivatives as androgen receptor modulator

Info

Publication number
TN2010000062A1
TN2010000062A1 TNP2010000062A TN2010000062A TN2010000062A1 TN 2010000062 A1 TN2010000062 A1 TN 2010000062A1 TN P2010000062 A TNP2010000062 A TN P2010000062A TN 2010000062 A TN2010000062 A TN 2010000062A TN 2010000062 A1 TN2010000062 A1 TN 2010000062A1
Authority
TN
Tunisia
Prior art keywords
androgen receptor
pyrrolidin
derivatives
receptor modulator
salt
Prior art date
Application number
TNP2010000062A
Other languages
English (en)
Inventor
Atsushi Hasuoka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TN2010000062A1 publication Critical patent/TN2010000062A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
TNP2010000062A 2007-08-07 2010-02-05 Pyrrolidin -2-one derivatives as androgen receptor modulator TN2010000062A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19
PCT/JP2008/064500 WO2009020234A2 (fr) 2007-08-07 2008-08-06 Composes d'amine cyclique

Publications (1)

Publication Number Publication Date
TN2010000062A1 true TN2010000062A1 (en) 2011-09-26

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000062A TN2010000062A1 (en) 2007-08-07 2010-02-05 Pyrrolidin -2-one derivatives as androgen receptor modulator

Country Status (34)

Country Link
US (2) US8420694B2 (fr)
EP (1) EP2176220B1 (fr)
JP (1) JP5292390B2 (fr)
KR (1) KR20100049644A (fr)
CN (1) CN101821235B (fr)
AR (1) AR067823A1 (fr)
AU (1) AU2008284662B2 (fr)
BR (1) BRPI0814957B8 (fr)
CA (1) CA2695852C (fr)
CL (1) CL2008002313A1 (fr)
CO (1) CO6160326A2 (fr)
CR (1) CR11266A (fr)
CY (1) CY1114067T1 (fr)
DK (1) DK2176220T3 (fr)
DO (1) DOP2010000053A (fr)
EA (1) EA017429B1 (fr)
ES (1) ES2406685T3 (fr)
GE (1) GEP20125571B (fr)
HR (1) HRP20130374T1 (fr)
JO (1) JO2864B1 (fr)
MA (1) MA31639B1 (fr)
ME (1) ME01579B (fr)
MX (1) MX2010001484A (fr)
MY (1) MY159910A (fr)
NZ (1) NZ583624A (fr)
PE (1) PE20090899A1 (fr)
PL (1) PL2176220T3 (fr)
PT (1) PT2176220E (fr)
RS (1) RS52812B (fr)
SI (1) SI2176220T1 (fr)
TN (1) TN2010000062A1 (fr)
TW (1) TWI418543B (fr)
WO (1) WO2009020234A2 (fr)
ZA (1) ZA201001289B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR067823A1 (es) * 2007-08-07 2009-10-21 Takeda Pharmaceutical Compuestos de amina ciclica
MX2010009162A (es) * 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009119880A1 (fr) * 2008-03-26 2009-10-01 Takeda Pharmaceutical Company Limited Dérivés pyrazole substitués et leur utilisation
EP2531029B1 (fr) 2010-02-04 2016-10-19 Radius Health, Inc. Modulateurs sélectifs du récepteur des androgènes
US20130053448A1 (en) 2010-05-12 2013-02-28 Louis O'Dea Therapeutic Regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
US20150057452A1 (en) * 2012-04-04 2015-02-26 Catylix, Inc. Selective androgen receptor modulators
EP2950790A4 (fr) 2012-08-09 2018-04-25 Dynamis Therapeutics, Inc. Méthodes destinées à préserver ou à améliorer la santé, le bien-être et/ou une fonction physiologique chez un sujet
CN104662124B (zh) * 2012-09-21 2017-06-16 默克专利股份有限公司 具有c‑c三键的化合物及其在液晶混合物中的用途
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CA2943611A1 (fr) 2014-03-28 2015-10-01 Duke University Methode de traitement du cancer faisant intervenir des modulateurs selectifs des recepteurs des ƒstrogenes
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
KR102792490B1 (ko) 2018-07-04 2025-04-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
CA3125929A1 (fr) 2019-01-11 2020-07-16 Grunenthal Gmbh Amides de pyrrolidine iii substitues
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
BR9914018A (pt) * 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
IL162340A0 (en) 2001-12-06 2005-11-20 Gtx Inc Treating muscle wasting with selective androgen receptor modulators
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
US20050101657A1 (en) 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
HRP20050038A2 (en) 2002-06-17 2005-08-31 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
WO2004016576A1 (fr) 2002-08-12 2004-02-26 Takeda Pharmaceutical Company Limited Derive de benzene a cycles accoles et son utilisation
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2005108351A1 (fr) * 2004-05-11 2005-11-17 Pfizer Products Inc. Derives de benzonitrile destines au traitement de la fragilite musculo-squelettique
AU2005247405A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
CA2543827C (fr) 2004-06-07 2010-03-09 James T. Dalton Modulateurs du recepteur d'androgene selectifs et leurs methodes d'utilisation
MX2007008334A (es) 2005-01-10 2007-09-11 Acadia Pharm Inc Derivados aminofenilo como moduladores de receptor de androgeno selectivos.
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
WO2006124447A2 (fr) 2005-05-13 2006-11-23 Eli Lilly And Company N-arylpyrrolidines substituees utilisees comme modulateurs selectifs du recepteur des androgenes
JP5070054B2 (ja) 2005-08-01 2012-11-07 武田薬品工業株式会社 環状アミン化合物
WO2007097289A1 (fr) 2006-02-20 2007-08-30 Takeda Pharmaceutical Company Limited Nouvelle substance pharmaceutique
AU2007275736A1 (en) * 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
KR20090034395A (ko) 2006-07-26 2009-04-07 노파르티스 아게 운데카프레닐 피로포스페이트 합성효소의 억제제
JP5241507B2 (ja) 2006-11-30 2013-07-17 武田薬品工業株式会社 環状アミン化合物
AR067823A1 (es) 2007-08-07 2009-10-21 Takeda Pharmaceutical Compuestos de amina ciclica

Also Published As

Publication number Publication date
EP2176220B1 (fr) 2013-03-27
GEP20125571B (en) 2012-07-10
WO2009020234A2 (fr) 2009-02-12
CR11266A (es) 2010-03-22
BRPI0814957B1 (pt) 2019-12-03
CA2695852A1 (fr) 2009-02-12
MA31639B1 (fr) 2010-08-02
HK1143972A1 (en) 2011-01-21
CN101821235A (zh) 2010-09-01
MY159910A (en) 2017-02-15
AR067823A1 (es) 2009-10-21
PL2176220T3 (pl) 2013-08-30
RS52812B (sr) 2013-10-31
DK2176220T3 (da) 2013-06-10
ES2406685T3 (es) 2013-06-07
CY1114067T1 (el) 2016-07-27
JP5292390B2 (ja) 2013-09-18
BRPI0814957B8 (pt) 2021-05-25
DOP2010000053A (es) 2010-07-15
MX2010001484A (es) 2010-03-04
PT2176220E (pt) 2013-04-09
JO2864B1 (en) 2015-03-15
NZ583624A (en) 2012-06-29
SI2176220T1 (sl) 2013-05-31
HRP20130374T1 (en) 2013-05-31
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28
CA2695852C (fr) 2017-01-03
AU2008284662A1 (en) 2009-02-12
CN101821235B (zh) 2012-11-14
TWI418543B (zh) 2013-12-11
CO6160326A2 (es) 2010-05-20
EP2176220A2 (fr) 2010-04-21
JP2010535704A (ja) 2010-11-25
WO2009020234A3 (fr) 2009-04-16
ZA201001289B (en) 2011-04-28
KR20100049644A (ko) 2010-05-12
US20090042967A1 (en) 2009-02-12
TW200916439A (en) 2009-04-16
EA201070246A1 (ru) 2010-08-30
BRPI0814957A2 (pt) 2015-02-03
PE20090899A1 (es) 2009-08-06
CL2008002313A1 (es) 2009-05-15
US7834051B2 (en) 2010-11-16
EA017429B1 (ru) 2012-12-28
AU2008284662B2 (en) 2013-07-25
US8420694B2 (en) 2013-04-16

Similar Documents

Publication Publication Date Title
TN2010000062A1 (en) Pyrrolidin -2-one derivatives as androgen receptor modulator
TN2011000286A1 (en) Spiroheterocyclic n-oxypiperidines as pesticides
EA201071201A1 (ru) ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71
TN2012000575A1 (en) Compositions and methods for modulating the wnt signaling pathway
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
HRP20120323T1 (en) Diarylhydantoin compounds
DK201100432A (en) New use
TW200744588A (en) Pharmaceutical composition for external use
WO2007005887A3 (fr) Composes de modulation des recepteur des androgenes et methodes associees
UA94833C2 (en) Substituted bicyclolactams
GEP20125426B (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
MX343625B (es) Composiciones plagicidas.
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
IN2012DN02876A (fr)
TW200800956A (en) 2-Aminopyrimidine derivatives
MX2009008921A (es) Derivados de tiazole en la forma de moduladores de receptores acoplados por proteina g.
TN2010000064A1 (en) Novel herbicides
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
MX2010001364A (es) Derivados de ciclopentandiona puenteados triciclicos como herbicidas.
GB201305247D0 (en) Amide Compounds
PH12015501146A1 (en) Hydantoin derivative
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
TN2010000094A1 (en) Novel herbicides
MX2011008126A (es) Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.